Studies have shown that when single CEA, SCC, Cyfra21-1, and NSE tests were performed on patients with esophageal cancer, the positive rates were 36.0, 53.5, 26.7, and 24.4%, respectively. This evidence concerns the gene CEACAM5 and esophageal cancer.